VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $11,356,000 | +143.9% | 1,111,112 | 0.0% | 29.98% | +77.5% |
Q2 2022 | $4,656,000 | -16.0% | 1,111,112 | 0.0% | 16.89% | -0.0% |
Q1 2022 | $5,544,000 | -25.8% | 1,111,112 | 0.0% | 16.90% | -10.6% |
Q4 2021 | $7,467,000 | +22.6% | 1,111,112 | 0.0% | 18.90% | +123.9% |
Q3 2021 | $6,089,000 | -16.2% | 1,111,112 | 0.0% | 8.44% | +9.6% |
Q2 2021 | $7,267,000 | -21.8% | 1,111,112 | 0.0% | 7.70% | -5.6% |
Q1 2021 | $9,289,000 | +34.0% | 1,111,112 | 0.0% | 8.16% | +58.0% |
Q3 2020 | $6,933,000 | +247.7% | 1,111,112 | +437.6% | 5.16% | +688.1% |
Q4 2018 | $1,994,000 | -68.2% | 206,663 | -58.7% | 0.66% | -52.6% |
Q3 2018 | $6,266,000 | -8.8% | 500,883 | -0.4% | 1.38% | -6.5% |
Q2 2018 | $6,869,000 | -39.2% | 502,825 | -11.1% | 1.48% | -40.0% |
Q1 2018 | $11,306,000 | +80.2% | 565,292 | +7.0% | 2.46% | +40.0% |
Q4 2017 | $6,273,000 | -32.9% | 528,422 | -13.2% | 1.76% | -31.6% |
Q3 2017 | $9,346,000 | +30.7% | 608,851 | -0.8% | 2.57% | +10.2% |
Q2 2017 | $7,152,000 | – | 613,601 | – | 2.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |